Greenleaf Trust purchased a new position in shares of Qiagen NV (NYSE:QGEN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 5,600 shares of the company’s stock, valued at approximately $228,000.
Several other large investors have also modified their holdings of QGEN. Lindbrook Capital LLC acquired a new position in Qiagen in the fourth quarter valued at $25,000. Captrust Financial Advisors lifted its holdings in Qiagen by 165.3% in the fourth quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock valued at $35,000 after buying an additional 628 shares during the period. Cornerstone Advisors Inc. acquired a new position in Qiagen in the first quarter valued at $44,000. Bremer Trust National Association acquired a new position in Qiagen in the fourth quarter valued at $45,000. Finally, Truvestments Capital LLC acquired a new position in Qiagen in the first quarter valued at $67,000. Institutional investors own 63.21% of the company’s stock.
NYSE:QGEN opened at $38.20 on Monday. The company has a quick ratio of 1.52, a current ratio of 1.69 and a debt-to-equity ratio of 0.54. The stock has a market cap of $8.61 billion, a PE ratio of 28.51, a price-to-earnings-growth ratio of 2.29 and a beta of 0.88. Qiagen NV has a one year low of $32.33 and a one year high of $41.55.
Several equities analysts have recently weighed in on the stock. Deutsche Bank reiterated a “buy” rating on shares of Qiagen in a report on Wednesday, May 8th. Goldman Sachs Group reiterated a “buy” rating on shares of Qiagen in a report on Tuesday, May 7th. Zacks Investment Research upgraded shares of Qiagen from a “sell” rating to a “buy” rating and set a $45.00 price objective on the stock in a report on Tuesday, April 16th. Finally, UBS Group assumed coverage on shares of Qiagen in a report on Friday, March 15th. They set a “neutral” rating and a $42.00 price objective on the stock. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $41.71.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Featured Article: Debt-To-Equity Ratio
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen NV (NYSE:QGEN).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.